Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ BitMine Immersion Technologies Stock Surges Wednesday: What′s Driving The Action? (Benzinga) +++ BITMINE IMMERSION Aktie +3,35%

STEVANATO Aktie

 >STEVANATO Aktienkurs 
13.9 EUR    +9.5%    (TradegateBSX)
Ask: 14.3 EUR / 1050 Stück
Bid: 13.8 EUR / 1100 Stück
Tagesumsatz: 776 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
STEVANATO Aktie über LYNX handeln
>STEVANATO Performance
1 Woche: -6,7%
1 Monat: -7,4%
3 Monate: -36,2%
6 Monate: -37,2%
1 Jahr: -26,9%
laufendes Jahr: -29,0%
>STEVANATO Aktie
Name:  STEVANATO GROUP SPA O.N.
Land:  Italien
Sektor:  Gesundheit
ISIN/ Wkn:  IT0005452658 / A3CUMB
Symbol/ Ticker:  87N (Frankfurt) / STVN (NYSE)
Kürzel:  FRA:87N, ETR:87N, 87N:GR, NYSE:STVN
Index:  -
Webseite:  https://www.stevanatogrou..
Profil:  Stevanato Group S.p.A. is a leading Italian manufacturer specializing in medical equipment, supplies, and distribution, with a strong global presence in the biopharmaceutical and diagnostic solutions ..
>Volltext..
Marktkapitalisierung:  3553.07 Mio. EUR
Unternehmenswert:  3893.26 Mio. EUR
Umsatz:  1116.39 Mio. EUR
EBITDA:  256.71 Mio. EUR
Nettogewinn:  133.9 Mio. EUR
Gewinn je Aktie:  0.49 EUR
Schulden:  456.36 Mio. EUR
Liquide Mittel:  114.85 Mio. EUR
Operativer Cashflow:  230.55 Mio. EUR
Bargeldquote:  0.24
Umsatzwachstum:  3.59%
Gewinnwachstum:  18.57%
Dividende je Aktie:  0.05 EUR
Dividendenrendite:  0.41%
Dividendenschätzung:  0.41%
Div. Historie:  05.06.25 - 0.054€
04.06.24 - 0.053€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  STEVANATO
Letzte Datenerhebung:  04.03.26
>STEVANATO Kennzahlen
Aktien/ Unternehmen:
Aktien: 49.71 Mio. St.
Frei handelbar: 100%
Rückkaufquote: 0.13%
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Buy
Kursziel: 71.17%
Bewertung:
KGV: 28.68
KGV lG: 26.44
KUV: 3.23
KBV: 2.64
PEG-Ratio: 1.17
EV/EBITDA: 15.17
Rentabilität:
Bruttomarge: 27.59%
Gewinnmarge: 11.99%
Operative Marge: 15.84%
Managementeffizenz:
Gesamtkaprendite: 5.85%
Eigenkaprendite: 9.81%
>STEVANATO Peer Group
Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege
 
04.03.26 - 16:31
Earnings Call Transkript: Stevanato Group übertrifft Prognosen für Q4 2025 – Aktie legt deutlich zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
04.03.26 - 15:15
Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
 
Stevanato (STVN) delivered earnings and revenue surprises of +6.06% and +4.96%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
04.03.26 - 12:39
Stevanato Group: Q4 Earnings Insights (Benzinga)
 
Importance Rank:  1 read more...
04.03.26 - 12:36
Stevanato Group Non-GAAP EPS of €0.18, revenue of €346.5M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.03.26 - 12:36
Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins (Business Wire)
 
- Establishes Fiscal 2026 Guidance -PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2025. Fourth Quarter and Full Year 2025 Highlights (comparisons to prior-year periods) For the fourth quarter of 2025, revenue increased 5% (7% on a constant currency basis) to €346.5 million, and high-value solutions represented 49% of total revenue. Gross profit margin increased 120 basis points to 30.9%, and adjusted EBITDA margin increased 70 basis points to 28.2%, for the fourth quarter of 2025. Diluted earnings per share were €0.17, and adjusted diluted earnings per share were €0.18 for the fourth quarter of 2025. For the fiscal year 2025, revenue increased 7% (9% on a constant currency basis) to €1.186 billion, and high-value solutions represented 46% of ...
19.02.26 - 12:33
Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026 (Business Wire)
 
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 4, 2026, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Wednesday, March 4, 2026, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Company's Investor Relations section of its website. Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: STVN conferenc...
16.01.26 - 13:24
Dätwyler mit Kooperation in USA im Bereich Selbstverabreichung von Medikamenten (Cash)
 
Industrie - Dätwyler geht in den USA eine Kooperation mit LTS Device Technologies und der Stevanato Group ein. Ziel ist die bequemere Verabreichung grösserer Medikamentenmengen, etwa bei Krebsbehandlungen....
16.01.26 - 13:01
Dätwyler mit Kooperation in USA im Bereich selbst-Verabreichung von Medikamenten (Cash)
 
- Der Industriekonzern Dätwyler ist in den USA eine Kooperation eingegangen. Gemeinsam mit LTS Device Technologies und der Stevanato Group strebt Dätwyler die Ausweitung des Anwendungsbereichs der subkutanen Verabreichung von Medikamenten in grossen Mengen an....
16.01.26 - 11:09
Datwyler, LTS Device Technologies, and Stevanato Group Collaborate to Expand Self-Delivery Options for Large-Volume Drugs (PR Newswire)
 
Enables convenient on-body delivery of higher dose therapies like anti-cancer treatments and monoclonal antibodies Utilizes a pre-verified large-volume platform solution to speed time to market Meets evolving industry needs amid shift from hospital to home administration PARIS, Jan. 16,......
24.12.25 - 16:00
Are Options Traders Betting on a Big Move in Stevanato Group Stock? (Zacks)
 
Investors need to pay close attention to STVN stock based on the movements in the options market lately....
19.11.25 - 13:30
Stevanato Group skizziert auf Londoner Konferenz Wachstumsstrategie im Pharmasektor/n (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
17.11.25 - 16:24
Stevanato Group skizziert Wachstumsstrategie: Fokus auf US-Expansion und hochwertige Lösungen (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
07.11.25 - 09:12
Stevanato Group reiterates 2025 outlook, projects high-value solutions to reach up to 44% of revenue as biologics demand accelerates (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.11.25 - 17:24
Stevanato (STVN) Q3 2025 Earnings Call Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
06.11.25 - 15:15
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
 
Stevanato (STVN) delivered earnings and revenue surprises of +14.29% and +5.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...
06.11.25 - 12:39
Stevanato Group Non-GAAP EPS of $0.14, revenue of €$303.2M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.11.25 - 12:33
Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025 (Business Wire)
 
Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were €0.13; adjusted diluted earnings per share were €0.14. Adjusted EBITDA margin increased 280 basis points to 25.7%. The Company is maintaining its fiscal 2025 guidance and continues to expect revenue in the range of €1.160 billion to €1.190 billion, adjusted EBITDA in the range of ...
22.10.25 - 12:36
Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
 
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Company's Investor Relations section of its website. Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: STVN conference call pre...
11.09.25 - 19:45
Stevanato (STVN) Upgraded to Buy: Here′s What You Should Know (Zacks)
 
Stevanato (STVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
05.08.25 - 15:00
Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates (Zacks)
 
Stevanato (STVN) delivered earnings and revenue surprises of +9.09% and +4.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer ein blindes Pferd verkaufen will, lobt die Füße. - Bauernregel - Bauernweisheit
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!